ArticleThrombosis journal2015
The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry.
Article in Thrombosis journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Global burden of venous thromboembolism: incidence and outcome estimates of deep-vein thrombosis and pulmonary embolism.Nature reviews. Cardiology · 2026Review
- Quality of life in oncological patients with venous thromboembolic disease.Research and practice in thrombosis and haemostasis · 2024Review
- Cost-of-Illness Analysis of Long-Term Health Care Resource Use and Disease Burden in Patients With Pulmonary Embolism: Insights From the PREFER in VTE Registry.Journal of the American Heart Association · 2022Article
- Pooled Analysis of Rivaroxaban therapy for acute venous thromboembolism in FIRST registry, SWIVTER and DRESDEN NOAC registry.Research and practice in thrombosis and haemostasis · 2022Article
- The venous thrombosis registry in Østfold Hospital (TROLL registry) - design and cohort description.Research and practice in thrombosis and haemostasis · 2022Article
- Rationale, design and methodology of TESEO study: a registry of thrombosis and neoplasia of SEOM (Spanish Society of Medical Oncology).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- Health-related quality of life and mortality in patients with pulmonary embolism: a prospective cohort study in seven European countries.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2019Article
- Comparison of quality of life measurements: EQ-5D-5L versus disease/treatment-specific measures in pulmonary embolism and deep vein thrombosis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2019Article
- Reliability and validity of the Maltese version of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q).Patient preference and adherence · 2019Article
- Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis.PloS one · 2019Article
- Validation and psychometric properties of the Maltese version of the Duke Anticoagulation Satisfaction Scale (DASS).Psychology research and behavior management · 2019Article
- Results and functional outcomes of en-bloc resection and vascular reconstruction in extremity musculoskeletal tumors.Acta orthopaedica et traumatologica turcica · 2018Article
- The impact of co-morbidity on the disease burden of VTE.Journal of thrombosis and thrombolysis · 2018Article
- Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study.Thrombosis journal · 2018Article
- Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE).Thrombosis and haemostasis · 2018Observational
- Recommended Methods for the Collection of Health State Utility Value Evidence in Clinical Studies.PharmacoEconomics · 2017Review
- The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry.Thrombosis and haemostasis · 2017Observational
- Direct oral anticoagulants and venous thromboembolism.European respiratory review : an official journal of the European Respiratory Society · 2016Review
- DOACs - advances and limitations in real world.Thrombosis journal · 2016Review
- Deep Vein Thrombosis in Europe-Health-Related Quality of Life and Mortality.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVenous thromboembolism (VTE) is a major health problem, with over one million events every year in Europe. However, there is a paucity of data on the current management in real life, including factors influencing treatment pathways, patient satisfaction, quality of life (QoL), and utilization of health care resources and the corresponding costs. The PREFER in VTE registry has been designed to address this and to understand medical care and needs as well as potential gaps for improvement. METHODS/
designThe PREFER in VTE registry was a prospective, observational, multicenter study conducted in seven European countries including Austria, France Germany, Italy, Spain, Switzerland, and the UK to assess the characteristics and the management of patients with VTE, the use of health care resources, and to provide data to estimate the costs for 12 months treatment following a first-time and/or recurrent VTE diagnosed in hospitals or specialized or primary care centers. In addition, existing anticoagulant treatment patterns, patient pathways, clinical outcomes, treatment satisfaction, and health related QoL were documented. The centers were chosen to reflect the care environment in which patients with VTE are managed in each of the participating countries. Patients were eligible to be enrolled into the registry if they were at least 18 years old, had a symptomatic, objectively confirmed first time or recurrent acute VTE defined as either distal or proximal deep vein thrombosis, pulmonary embolism or both. After the baseline visit at the time of the acute VTE event, further follow-up documentations occurred at 1, 3, 6 and 12 months. Follow-up data was collected by either routinely scheduled visits or by telephone calls.
resultsOverall, 381 centers participated, which enrolled 3,545 patients during an observational period of 1 year.
conclusionThe PREFER in VTE registry will provide valuable insights into the characteristics of patients with VTE and their acute and mid-term management, as well as into drug utilization and the use of health care resources in acute first-time and/or recurrent VTE across Europe in clinical practice.
trial registrationRegistered in DRKS register, ID number: DRKS00004795.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.